百时美施贵宝-话题@MedSci

#百时美施贵宝#

35篇内容 | 1238人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1353484, encodeId=d4d21353484a3, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果, objectType=article, longId=163563, objectId=b02416356319, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b02416356319, replyNumber=0, likeNumber=36, createdTime=2019-04-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b02416356319, moduleTitle=百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b02416356319)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353483, encodeId=949a1353483b8, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, objectType=article, longId=158911, objectId=f601158911df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f601158911df, replyNumber=0, likeNumber=36, createdTime=2019-01-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f601158911df, moduleTitle=百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f601158911df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353482, encodeId=4107135348288, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=重磅突发！百时美施贵宝宣布740亿美元收购新基, objectType=article, longId=157273, objectId=0ef115e273a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ef115e273a4, replyNumber=0, likeNumber=0, createdTime=2019-01-05, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ef115e273a4, moduleTitle=重磅突发！百时美施贵宝宣布740亿美元收购新基, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ef115e273a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353481, encodeId=4d47135348156, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=改革开放40周年百时美施贵宝荣获双料殊荣, objectType=article, longId=154958, objectId=6ef215495894, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ef215495894, replyNumber=0, likeNumber=40, createdTime=2018-12-03, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ef215495894, moduleTitle=改革开放40周年百时美施贵宝荣获双料殊荣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ef215495894)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353480, encodeId=6e861353480a8, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝欧狄沃™三季度即将登陆中国, objectType=article, longId=146555, objectId=bf9c1465557e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9c1465557e, replyNumber=0, likeNumber=40, createdTime=2018-08-15, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9c1465557e, moduleTitle=百时美施贵宝欧狄沃™三季度即将登陆中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf9c1465557e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353479, encodeId=b68a13534e99c, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝荣获“2017年度创新企业”奖项, objectType=article, longId=128143, objectId=ad5a12814331, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad5a12814331, replyNumber=0, likeNumber=31, createdTime=2018-01-31, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad5a12814331, moduleTitle=百时美施贵宝荣获“2017年度创新企业”奖项, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad5a12814331)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353478, encodeId=d46713534e862, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, objectType=article, longId=94937, objectId=aed19493eed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aed19493eed, replyNumber=0, likeNumber=36, createdTime=2017-04-08, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aed19493eed, moduleTitle=百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aed19493eed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353477, encodeId=92ac13534e723, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物, objectType=article, longId=35568, objectId=2a283556847, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a283556847, replyNumber=0, likeNumber=43, createdTime=2014-05-31, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a283556847, moduleTitle=百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a283556847)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353476, encodeId=f57713534e6c2, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%, objectType=article, longId=33503, objectId=8e5c33503d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e5c33503d1, replyNumber=0, likeNumber=32, createdTime=2014-04-18, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e5c33503d1, moduleTitle=百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e5c33503d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353475, encodeId=bfb913534e503, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=阿斯利康-百时美施贵宝糖尿病新药Xigduo获欧盟批准, objectType=article, longId=29872, objectId=6f49298e2c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f49298e2c4, replyNumber=0, likeNumber=41, createdTime=2014-01-25, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f49298e2c4, moduleTitle=阿斯利康-百时美施贵宝糖尿病新药Xigduo获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f49298e2c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353474, encodeId=a11613534e487, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=CHMP建议批准阿斯利康和百时美施贵宝降糖新药Xigduo, objectType=article, longId=27142, objectId=6f712e142a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6f712e142a5, replyNumber=0, likeNumber=34, createdTime=2013-11-28, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6f712e142a5, moduleTitle=CHMP建议批准阿斯利康和百时美施贵宝降糖新药Xigduo, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6f712e142a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353473, encodeId=b5f213534e36d, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝抑郁药BMS-820836 II期试验失败, objectType=article, longId=23002, objectId=c9752300260, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9752300260, replyNumber=0, likeNumber=50, createdTime=2013-08-17, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9752300260, moduleTitle=百时美施贵宝抑郁药BMS-820836 II期试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9752300260)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353472, encodeId=4f6013534e26d, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请（sNDA）, objectType=article, longId=21572, objectId=b9d4215e217, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9d4215e217, replyNumber=0, likeNumber=31, createdTime=2013-07-19, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9d4215e217, moduleTitle=FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请（sNDA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9d4215e217)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353471, encodeId=b65313534e1f1, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝HCV双口服疗法在II期试验中显示出良好疗效, objectType=article, longId=5773, objectId=83145e7385, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=83145e7385, replyNumber=0, likeNumber=43, createdTime=2012-04-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=83145e7385, moduleTitle=百时美施贵宝HCV双口服疗法在II期试验中显示出良好疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83145e7385)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1353470, encodeId=10cd13534e0e9, content=<a href='/topic/show?id=43abe1883b6' target=_blank style='color:#2F92EE;'>#百时美施贵宝#</a>, objectTitle=百时美施贵宝25亿美元收购丙肝药商Inhibitex, objectType=article, longId=3703, objectId=39fd3e036a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39fd3e036a, replyNumber=0, likeNumber=29, createdTime=2012-01-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39fd3e036a, moduleTitle=百时美施贵宝25亿美元收购丙肝药商Inhibitex, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39fd3e036a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

百时美施贵宝

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝公布欧狄沃（纳武利尤单抗注射液）治疗经治非小细胞肺癌患者的长期生存汇总分析结果

2019-04-05

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝的PD-1单抗Opdivo未来增长前景堪忧

2019-01-27

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

重磅突发！百时美施贵宝宣布740亿美元收购新基

2019-01-05

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

改革开放40周年百时美施贵宝荣获双料殊荣

2018-12-03

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝欧狄沃™三季度即将登陆中国

2018-08-15

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝荣获“2017年度创新企业”奖项

2018-01-31

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝 Opdivo 治疗转移性结肠直肠癌获得 FDA 优先审查

2017-04-08

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝将与CytomX及Incyte合作共同开发免疫肿瘤药物

2014-05-31

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝丙型肝炎复方药物在后期试验中治愈率达90%

2014-04-18

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

阿斯利康-百时美施贵宝糖尿病新药Xigduo获欧盟批准

2014-01-25

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

CHMP建议批准阿斯利康和百时美施贵宝降糖新药Xigduo

2013-11-28

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝抑郁药BMS-820836 II期试验失败

2013-08-17

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

FDA接受百时美施贵宝及辉瑞Eliquis补充新药申请（sNDA）

2013-07-19

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝HCV双口服疗法在II期试验中显示出良好疗效

2012-04-27

zhaojie88 (审核中...)

前往app查看评论内容

#百时美施贵宝#

百时美施贵宝25亿美元收购丙肝药商Inhibitex

2012-01-21

科室
- - 订阅+
  - 更多科室
工具
服务